Enhancement by 06mbenzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N-nitrosourea therapeutic index on nude mice bearing resistant human melanoma
1997

Enhancement of Cystemustine Effectiveness by BNAG in Melanoma Treatment

Sample size: 40 publication Evidence: moderate

Author Information

Author(s): E Debiton, C Cussac-Buchdhal, E Mounetou, M Rapp, JM Dupuy, J-C Maurizis, A Veyre, J-C Madelmont

Primary Institution: Institut National de la Sante et de la Recherche Medicale

Hypothesis

Does the combination of 06-benzyl-N2-acetylguanosine (BNAG) and cystemustine improve the therapeutic index against resistant human melanoma in mice?

Conclusion

The study demonstrates that BNAG significantly enhances the therapeutic index of cystemustine, leading to improved tumor growth inhibition.

Supporting Evidence

  • BNAG significantly increased the efficiency of cystemustine against M4Beu melanoma cells.
  • The combination treatment showed a linear increase in toxicity with BNAG.
  • BNAG alone did not display general signs of toxicity up to 640 mg kg-1.
  • Statistical analysis indicated significant differences in tumor volume between treatment groups.

Takeaway

When given together, BNAG helps a cancer drug work better against melanoma in mice, making it more effective at stopping tumor growth.

Methodology

The study involved administering cystemustine alone and in combination with BNAG to nude mice bearing human melanoma, comparing their effects on tumor growth and toxicity.

Potential Biases

Potential bias in the selection of doses and treatment schedules may affect the results.

Limitations

The study's findings may not directly translate to human patients due to differences in metabolism and tumor biology.

Participant Demographics

Nude mice bearing Mer+ M4Beu human melanoma cells.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication